Biomerica Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Biomerica Inc 's ROA in the fourth quarter of 2026?
Biomerica Inc recorded a cumulative net loss of $-4 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -42.95%.

However, within the Healthcare sector 624 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the May 31 2026 quarter, so far to 4127, from total ROA ranking in the third quarter of 2026 at 4717.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(May 31 2026) IV. Quarter	(Feb 28 2026) III. Quarter	(Nov 30 2025) II. Quarter	(Aug 31 2025) I. Quarter	(May 31 2025) IV. Quarter
Y / Y Total Assets Change	208.11 %	-32.35 %	-36.41 %	-13.19 %	-36.41 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-4	-4	-4	-4	-5
Return On Assets (TTM)	-42.95 %	-72.19 %	-63.24 %	-50.82 %	-66.79 %
BMRA's Total Ranking	# 4127	# 4717	# 4015	# 4239	# 4241
Total Assets (TTM) in million	18	5	6	7	6
Seq. Total Assets Change	265.09 %	-15.61 %	-13.59 %	15.73 %	-19.84 %
Seq. Net Income Change	-	-	-	-	-

BMRA's 5 Years Annual ROA >> Back to BMRA Management Effectiveness >> Compare BMRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 10
Sector	# 625
Overall	# 4011

Return On Assets Statistics
High	Average	Low
14.24 %	-29.55 %	-70.68 %
(May 31 2017)		(Feb 28 2026)

Financial Statements
Biomerica Inc 's Assets	$ 18 million	BMRA's Balance sheet
Biomerica Inc 's Income	$ -1 million	Quarterly BMRA's Income Statement
BMRA's Income by Division		See BMRA's Income by Division

Annual Return On Assets	(May 31 2026) FY 2026	(May 31 2025) FY 2025	(May 31 2024) FY 2024	(May 31 2023) FY 2023	(May 31 2022) FY 2022
Y / Y Total Assets Change	208.11 %	-36.41 %	-35.88 %	31.11 %	-0.23 %
Total Assets in million	18	6	9	14	11
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-4	-5	-6	-7	-5
Annual Return On Assets	-21.2 %	-86.04 %	-65.77 %	-50.37 %	-41.91 %

BMRA's 5 Years Annual ROA >> Back to BMRA Management Effectiveness >> Compare BMRA ROA to its Competitors

More Return On Assets Ratios
BMRA's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BMRA's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BMRA's Competitors
Subscribers only: Roa for Biomerica Inc 's Suppliers
Subscribers only: Return On Assets for BMRA's Customers

You may also want to know
BMRA's Roi	BMRA's Inventory Turnover Ratio	BMRA's Growth Rates	BMRA's Dividend Comparisons
	BMRA's Profitability Ratios	BMRA's Asset Turnover Ratio	BMRA's Dividend Growth
BMRA's Roe	BMRA's Valuation Ratios	BMRA's Financial Strength Ratios	BMRA's Dividend Payout Ratio

Companies with similar Return On Assets at May 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T08:34:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.